P2, N=60, Not yet recruiting, Oncolytics Biotech

Moreover, the combination of San with copper ionophores (Elesclomol-CuCl 2) exhibits synergistic effects in promoting cuproptosis...Surface plasmon resonance experiments and cellular thermal shift assay confirm that San strongly interacts with FDX1 and markedly enhances the thermostability of FDX1. In conclusion, our findings indicate that San substantially inhibits the progression of HCC by targeting FDX1/LIAS/DLAT/HSP70 axis-dependent cuproptosis.

BP is an effective adjunct to ATO therapy, counteracting gut dysbiosis, intestinal damage, and the immune microenvironment while synergistically improving antileukemic efficacy. Targeting the gut-leukemia axis with BP represents a promising strategy for improving the precision and safety of APL treatment.

The combination enhanced the p53 expression. Our findings elucidate the mechanism underlying this synergistic interaction and underscore the potential of p53 status as a predictive biomarker for identifying patients most likely to benefit from HHT and gilteritinib combination therapy.

Here, through a small-molecule compound screening, we identify elesclomol, a potent copper ionophore, which sensitizes BRCA-proficient ovarian cancer cells to PARPi by inhibiting activation of the ATR-CHK1 pathway...Importantly, we reveal a secondary metabolic vulnerability in PARPi-resistant ovarian cancer associated with de novo pyrimidine synthesis, suggesting that targeting this pathway as an effective strategy to eradicate drug-adaptive residual tumors and resistant patient-derived xenograft models following ATR and PARP co-inhibition. These findings propose de novo pyrimidine synthesis as an adaptive metabolic vulnerability that can be therapeutically targeted to overcome PARPi resistance in BRCA-proficient ovarian cancer.

Leveraging this biomimetic platform, we conducted high-throughput drug screening and identified lurbinectedin as a potent therapeutic candidate for TETs...Integrating RNAseq data with TCGA survival analysis further identified PBX3, REPS2, and CXCR4 as potential efficacy-predictive biomarkers. This study establishes a translational framework linking 3D bioprinted TET models with biomarker discovery, offering a standardized platform for precision drug screening and mechanistic exploration in thymic epithelial tumors.

P1/2, N=63, Recruiting, Children's Hospital of Philadelphia | Trial primary completion date: Jul 2026 --> Jul 2027

After treatment with all-trans retinoic acid and arsenic trioxide, he developed localized penile ulcers resistant to antibiotics. The ulcers improved following chemotherapy with daunorubicin and azacitidine. This case highlights penile ulcerations as a rare manifestation of leukemia cutis in APML, underscoring the importance of considering leukemic infiltration in differential diagnosis of genital ulcers when infectious causes are excluded.

Induction therapy with all-trans-retinoic acid and arsenic trioxide resulted in hematologic remission...Atypical clinical trajectories should prompt careful assessment of marrow morphology and immunophenotypic features. Continued characterization of such cases may refine diagnostic criteria and direct individualized approaches to therapy.

P1/2, N=44, Terminated, Antiva Biosciences | N=110 --> 44 | Trial completion date: Jun 2025 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Oct 2025; Study terminated early due to Antiva business decision.

Furthermore, flow cytometry and colony formation assays revealed that PCZ attenuates and reduces the apoptotic/necrotic effects of ATO. In conclusion, PCZ synergistically and effectively reduces the adverse cytotoxic effects of ATO in lung cancer cells, providing a promising new therapeutic strategy for lung cancer treatment.

P1/2, N=141, Active, not recruiting, Antiva Biosciences | Recruiting --> Active, not recruiting | Trial completion date: Feb 2026 --> Jun 2026